Selected article for: "adverse outcome and H1N1 infection"
Author: Zhiheng Xu; Jianmeng Zhou; Yongbo Huang; Xuesong Liu; Yonghao Xu; Sibei Chen; Dongdong Liu; Zhimin Lin; Xiaoqing Liu; Yimin Li
Title: The efficacy of convalescent plasma for the treatment of severe influenza
  • Document date: 2020_2_23
    • ID: 4pe9o59g_28
    Snippet: All of the 5 studies were multicenter randomized controlled trials. Hung et al had found that hyperimmune IV immunoglobulin (H-IVIG) administrated within 5 days of symptom onset was associated with a lower viral load and reduced mortality in patients with severe H1N1 infection (17) . The pilot study from INSIGHT FLU005 IVIG Pilot Study Group showed that H-IVIG administration significantly increased hemagglutination inhibition (HAI) titer levels a.....
    Document: All of the 5 studies were multicenter randomized controlled trials. Hung et al had found that hyperimmune IV immunoglobulin (H-IVIG) administrated within 5 days of symptom onset was associated with a lower viral load and reduced mortality in patients with severe H1N1 infection (17) . The pilot study from INSIGHT FLU005 IVIG Pilot Study Group showed that H-IVIG administration significantly increased hemagglutination inhibition (HAI) titer levels among patients with influenza (18). Later, they performed an international, double-blind RCT, which shown that hIVIG had similar safety outcome of death and adverse events (15) . Furthermore, Beigel et al did a multicenter phase 2 trial and found that immune plasma provided support for a possible benefit of severe influenza (19). Recently, their phase 3 trial had shown that high-titre anti-influenza plasma conferred no significant benefit of severe influenza A (14) ( Table 1) .

    Search related documents:
    Co phrase search for related documents
    • adverse event and double blind: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57
    • adverse event and immune plasma: 1
    • adverse event and multicenter phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • adverse event and pilot study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • adverse event and possible benefit: 1, 2
    • adverse event and reduced mortality: 1, 2, 3, 4, 5, 6
    • adverse event and safety outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • adverse event and significant benefit: 1, 2, 3
    • adverse event and symptom onset: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • adverse event and viral load: 1, 2, 3, 4, 5, 6
    • adverse event death and control trial: 1
    • adverse event death and safety outcome: 1
    • adverse event death and symptom onset: 1
    • anti influenza plasma and H1N1 infection: 1
    • anti influenza plasma and HAI titer: 1
    • anti influenza plasma and hemagglutination inhibition: 1
    • anti influenza plasma and high titre: 1
    • anti influenza plasma and high titre anti influenza plasma: 1
    • anti influenza plasma and immune plasma: 1, 2, 3, 4, 5, 6